Scholarlink

Background <p>We address the therapeutic relevance of glioblastoma (GBM)’s molecular characterization, focusing on whether a proneural-vs-mesenchymal classification may describe GBM heterogeneity, correlate to stemness and CD44 (a marker often, but conflictingly, used in GBM), and have a prognostic value in terms of temozolomide (TMZ) resistance.</p> Methods <p>We molecularly profiled 4 patient-derived GBM cells (PD-GBM) and a reference cell line (U87), validating the results in public datasets (PD-GBM, TCGA-GBM), then studying the subtype-specific response to TMZ in vitro, both under normoxia and simulated hypoxia.</p> Results <p>Firstly, the proneural subtype transcriptionally and phenotypically correlates with higher stemness. Secondly, CD44 inversely correlates to stemness, acting as a mesenchymal marker both intra-tumorally (FACS-sorted CD44<sup>LOW</sup> cells had higher stemness than CD44<sup>HIGH</sup>) and inter-tumorally (also in larger datasets). Further, mesenchymal PD-GBM cells are also enriched in other hyaluronic acid (HA) surface receptors, proneural in matrix HA receptors. Finally, although TMZ stimulates a general mesenchymal shift in all cells, there are proneural-specific responses: this subtype resists TMZ better under hypoxia (vs. normoxia) in a first treatment, and in a second treatment (vs. single) under normoxia.</p> Conclusion <p>PD-GBM show clear proneural/stemness and mesenchymal/CD44 correlations, which may bear prognostic significance, as more proneural/stem GBMs appeared more capable to develop TMZ resistance.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Molecular subtypes and the (in vitro) response of glioblastoma to temozolomide

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月8日

查看全文
  • Silvia Rancati,
  • Matilde Campolungo,
  • Gerusa Duarte Dalmolin,
  • Pierre Lau,
  • Federica Furia,
  • Alessandro Coppe,
  • Fabio Landuzzi,
  • Manuela Vecchi,
  • Andrea Cavalli,
  • Stefano Gustincich,
  • Nicola Tirelli

摘要

Background

We address the therapeutic relevance of glioblastoma (GBM)’s molecular characterization, focusing on whether a proneural-vs-mesenchymal classification may describe GBM heterogeneity, correlate to stemness and CD44 (a marker often, but conflictingly, used in GBM), and have a prognostic value in terms of temozolomide (TMZ) resistance.

Methods

We molecularly profiled 4 patient-derived GBM cells (PD-GBM) and a reference cell line (U87), validating the results in public datasets (PD-GBM, TCGA-GBM), then studying the subtype-specific response to TMZ in vitro, both under normoxia and simulated hypoxia.

Results

Firstly, the proneural subtype transcriptionally and phenotypically correlates with higher stemness. Secondly, CD44 inversely correlates to stemness, acting as a mesenchymal marker both intra-tumorally (FACS-sorted CD44LOW cells had higher stemness than CD44HIGH) and inter-tumorally (also in larger datasets). Further, mesenchymal PD-GBM cells are also enriched in other hyaluronic acid (HA) surface receptors, proneural in matrix HA receptors. Finally, although TMZ stimulates a general mesenchymal shift in all cells, there are proneural-specific responses: this subtype resists TMZ better under hypoxia (vs. normoxia) in a first treatment, and in a second treatment (vs. single) under normoxia.

Conclusion

PD-GBM show clear proneural/stemness and mesenchymal/CD44 correlations, which may bear prognostic significance, as more proneural/stem GBMs appeared more capable to develop TMZ resistance.